Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Average Recommendation of “Buy” by Brokerages

Tenax Therapeutics, Inc. (NASDAQ:TENX) has earned a consensus recommendation of “Buy” from the five brokerages that are covering the company, Marketbeat reports. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $16.00.

Several brokerages recently issued reports on TENX. Leerink Partners began coverage on Tenax Therapeutics in a report on Thursday, October 24th. They set an “outperform” rating and a $16.00 price objective for the company. Guggenheim assumed coverage on Tenax Therapeutics in a research report on Monday, October 14th. They issued a “buy” rating and a $16.00 target price on the stock. William Blair began coverage on Tenax Therapeutics in a report on Monday, September 30th. They set an “outperform” rating for the company. Leerink Partnrs upgraded Tenax Therapeutics to a “strong-buy” rating in a report on Thursday, October 24th. Finally, StockNews.com assumed coverage on shares of Tenax Therapeutics in a research note on Thursday, September 26th. They issued a “sell” rating for the company.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in TENX. Vestal Point Capital LP bought a new stake in Tenax Therapeutics during the third quarter worth approximately $288,000. Sphera Funds Management LTD. acquired a new stake in shares of Tenax Therapeutics in the third quarter worth $101,000. Finally, Stonepine Capital Management LLC bought a new stake in shares of Tenax Therapeutics during the 3rd quarter worth $173,000. 1.67% of the stock is owned by institutional investors.

Tenax Therapeutics Stock Performance

TENX stock opened at $5.88 on Friday. The company has a 50 day moving average of $4.76 and a two-hundred day moving average of $3.95. Tenax Therapeutics has a 12-month low of $2.77 and a 12-month high of $27.33.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.